Thyroid Eye Disease

Endocrinology
11
Pipeline Programs
6
Companies
16
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
5
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

Amgen
TEPEZZAApproved
teprotumumab
Amgen
Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]injection2020

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
3 programs
1
1
1
TeprotumumabPhase 4Monoclonal Antibody5 trials
TeprotumumabPhase 3Monoclonal Antibody1 trial
AMG 732Phase 21 trial
Active Trials
NCT07438405Not Yet Recruiting30Est. Jul 2028
NCT03461211Completed51Est. Feb 2021
NCT04040894Approved For Marketing
+4 more trials
Immunovant
ImmunovantDURHAM, NC
2 programs
2
BatoclimabPhase 3Monoclonal Antibody1 trial
BatoclimabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT05517421CompletedEst. Nov 2025
NCT05524571Active Not RecruitingEst. Mar 2026
argenx
argenxBelgium - Zwijnaarde
2 programs
2
Efgartigimod PH20 SCPhase 31 trial
Efgartigimod PH20 SCPhase 31 trial
Active Trials
NCT06307613Terminated102Est. Feb 2026
NCT06307626Terminated105Est. Feb 2026
Lassen Therapeutics
Lassen TherapeuticsCA - San Diego
1 program
1
LASN01Phase 21 trial
Active Trials
NCT06226545CompletedEst. Apr 2025
Tourmaline Bio
Tourmaline BioNY - New York
1 program
1
TOUR006 - 20 MGPhase 21 trial
Active Trials
NCT06088979RecruitingEst. Sep 2027
Zenas BioPharma
Zenas BioPharmaWALTHAM, MA
1 program
1
ZB001 for injectionPhase 11 trial
Active Trials
NCT05776121Completed17Est. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AmgenTeprotumumab
argenxEfgartigimod PH20 SC
argenxEfgartigimod PH20 SC
ImmunovantBatoclimab
ImmunovantBatoclimab
AmgenTeprotumumab
AmgenAMG 732
Lassen TherapeuticsLASN01
Tourmaline BioTOUR006 - 20 MG
AmgenTeprotumumab
Zenas BioPharmaZB001 for injection
AmgenTeprotumumab
AmgenTeprotumumab
AmgenTeprotumumab
AmgenTeprotumumab

Clinical Trials (16)

Total enrollment: 776 patients across 16 trials

NCT05002998AmgenTeprotumumab

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Start: Sep 2021Est. completion: Dec 2025313 patients
Phase 4Completed
NCT06307626argenxEfgartigimod PH20 SC

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

Start: Mar 2024Est. completion: Feb 2026105 patients
Phase 3Terminated
NCT06307613argenxEfgartigimod PH20 SC

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Start: Mar 2024Est. completion: Feb 2026102 patients
Phase 3Terminated
NCT05524571ImmunovantBatoclimab

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Start: Jan 2023Est. completion: Mar 2026
Phase 3Active Not Recruiting
NCT05517421ImmunovantBatoclimab

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Start: Nov 2022Est. completion: Nov 2025
Phase 3Completed
NCT03461211AmgenTeprotumumab

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Start: Apr 2018Est. completion: Feb 202151 patients
Phase 3Completed
NCT07438405AmgenAMG 732

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

Start: Feb 2026Est. completion: Jul 202830 patients
Phase 2Not Yet Recruiting
NCT06226545Lassen TherapeuticsLASN01

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Start: Mar 2024Est. completion: Apr 2025
Phase 2Completed
NCT06088979Tourmaline BioTOUR006 - 20 MG

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease

Start: Feb 2024Est. completion: Sep 2027
Phase 2Recruiting
NCT01868997AmgenTeprotumumab

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Start: Jul 2013Est. completion: Feb 201788 patients
Phase 2Completed
NCT05776121Zenas BioPharmaZB001 for injection

Study of ZB001 in Chinese Patients With Thyroid Eye Disease

Start: May 2023Est. completion: Apr 202417 patients
Phase 1Completed
NCT06674941AmgenTeprotumumab

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

Start: Mar 2023Est. completion: Nov 202344 patients
Phase 1Completed
NCT06389578AmgenTeprotumumab

A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease

Start: Jul 2022Est. completion: Sep 202316 patients
Phase 1Completed
NCT02103283AmgenTeprotumumab

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Start: Oct 2014Est. completion: Aug 20165 patients
Phase 1Completed
NCT04040894AmgenTeprotumumab

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

N/AApproved For Marketing
NCT07085117AmgenTeprotumumab

Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients

Start: Jul 2025Est. completion: Aug 20255 patients
N/ACompleted

Related Jobs in Endocrinology

Research Associate I/II - Biology

Marea Therapeutics
South San Francisco
1w ago
$90K - $120K/yr

Associate Director, Clinical Operations

Marea Therapeutics
South San Francisco
3w ago
$190K - $210K/yr

Associate Director/Director, Regulatory Affairs

Marea Therapeutics
South San Francisco
1mo ago
$185K - $240K/yr

Medical Science Liaison (rare diseases)

Amgen
Poland - Lódz
1mo ago

Senior/Executive Director, Analytical Development

Marea Therapeutics
South San Francisco
1mo ago
$250K - $295K/yr

Senior Clinical Scientist - Job ID: 1845

Ascendis Pharma
Palo Alto, California (Hybrid)
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 776 patients
6 companies competing in this space

Related Indications

Acromegaly(67)Growth Hormone Deficiency(39)Growth Hormone Disorder(37)Hypogonadism(21)Secondary Hyperparathyroidism(13)Hypoparathyroidism(12)Adult Growth Hormone Deficiency(10)Hypothyroidism(9)Cushing's Syndrome(9)Growth Hormone Deficiency in Children(5)